Key Takeaways
- Testosterone replacement therapy (TRT) and human chorionic gonadotropin (HCG) serve different purposes. TRT replaces testosterone, while HCG mimics luteinizing hormone (LH) to stimulate the testes.
- TRT can suppress the body’s natural production of LH and follicle-stimulating hormone (FSH), potentially reducing intratesticular testosterone, sperm production, and testicular volume.
- Clinical studies suggest that low-dose HCG may help maintain intratesticular testosterone during TRT and may help preserve spermatogenesis in some men, although it does not guarantee fertility.
- HCG is not necessary for every patient receiving TRT. Whether it should be included depends on fertility goals, symptoms, laboratory findings, and individual medical circumstances.
- Decisions about hormone therapy should always be made with a licensed healthcare provider after a comprehensive medical evaluation.
What HCG Does Inside a Modern TRT Protocol
“If TRT works so well, why do some treatment protocols include HCG?”
HCG may be prescribed alongside testosterone replacement therapy (TRT) in selected patients to help maintain testicular function and support fertility potential. Treatment should always be individualized and supervised by a licensed healthcare provider.
It’s a reasonable question. Testosterone replacement therapy (TRT) is highly effective at restoring testosterone levels in men with clinically confirmed hypogonadism, yet many patients discover that some clinicians recommend adding another injectable medication: human chorionic gonadotropin (HCG).
At first glance, HCG can seem like an unnecessary extra expense. It adds another prescription, another injection schedule, and additional monitoring. However, TRT and HCG perform fundamentally different biological functions.
TRT supplies testosterone from outside the body. HCG helps stimulate one of the body’s natural hormone signaling pathways by acting like luteinizing hormone (LH), the pituitary hormone responsible for signaling the testes to produce testosterone.
That distinction matters because testosterone therapy changes how the hypothalamic-pituitary-gonadal (HPG) axis functions. As testosterone levels increase from external treatment, the brain reduces its production of LH and follicle-stimulating hormone (FSH). Over time, this reduction may decrease intratesticular testosterone—the high local testosterone concentration inside the testes that is essential for normal sperm production (Bhasin et al., 2018).
For some men, particularly those who hope to preserve fertility or maintain testicular function while receiving TRT, HCG may help support this pathway. For others, it may provide little additional benefit.
Importantly, HCG is not a fertility guarantee. It does not replace FSH, it does not prevent every consequence of TRT-related gonadotropin suppression, and it does not ensure that natural testosterone production will recover quickly if TRT is discontinued. Current evidence supports its use in selected patients—not as a universal component of every TRT protocol (Mulhall et al., 2018).
Understanding what HCG actually does—and what it does not do—can help patients have a more informed discussion with their healthcare provider before beginning hormone therapy.
What Is HCG?
Human chorionic gonadotropin (HCG) is a naturally occurring hormone produced during pregnancy, where it helps maintain early pregnancy by supporting the corpus luteum. Although best known for this role, HCG has important medical applications in men because its molecular structure closely resembles luteinizing hormone (LH).
LH is one of the key hormones produced by the pituitary gland. After receiving signals from the hypothalamus, the pituitary releases LH into the bloodstream, where it binds to receptors on Leydig cells within the testes. These cells respond by producing testosterone.
Because HCG binds to the same LH receptor, it can stimulate Leydig cells in much the same way as endogenous LH.
This is an important distinction because serum testosterone and intratesticular testosterone are not the same thing.
Most laboratory testing measures testosterone circulating in the bloodstream. However, sperm production depends on testosterone concentrations inside the testes, where intratesticular testosterone levels are normally many times higher than serum levels (Coviello et al., 2005).
When TRT suppresses LH production, circulating testosterone may remain normal—or even above normal—while intratesticular testosterone falls substantially.
In one landmark randomized study, Coviello and colleagues demonstrated that relatively low doses of HCG maintained intratesticular testosterone in healthy men despite suppression of endogenous gonadotropins by exogenous testosterone (Coviello et al., 2005). This finding helps explain why HCG is sometimes used alongside TRT in carefully selected patients.
However, maintaining intratesticular testosterone should not be confused with guaranteeing fertility. Human reproduction depends on multiple hormones, including FSH, along with normal testicular function, genetics, age, and overall health.
HCG is a prescription medication regulated by the U.S. Food and Drug Administration. It is not a dietary supplement, and it should only be used under medical supervision because dosing, monitoring, and potential adverse effects require individualized clinical judgment.
Why TRT Can Affect Fertility and Testicular Function
To understand why HCG may be considered during TRT, it helps to understand how testosterone production is normally regulated.
The hypothalamus releases gonadotropin-releasing hormone (GnRH), which stimulates the pituitary gland to produce LH and FSH. LH signals the Leydig cells to produce testosterone, while FSH acts primarily on Sertoli cells to support sperm development.
Together, these hormones form the hypothalamic-pituitary-gonadal (HPG) axis, a tightly regulated feedback system that maintains hormone balance.
When testosterone is administered from an external source, the brain detects the increase in circulating androgen levels. In response, it reduces secretion of GnRH, LH, and FSH. This negative feedback is an expected pharmacological effect of TRT and not a complication unique to any particular treatment method (Bhasin et al., 2018).
As LH declines, the testes receive less stimulation. Endogenous testosterone production decreases, intratesticular testosterone levels fall, and sperm production may decline. Some men also experience a reduction in testicular volume due to decreased testicular activity.
The extent of suppression varies considerably between individuals. Factors such as baseline fertility, age, duration of therapy, testosterone dose, and underlying medical conditions all influence how the reproductive system responds.
Importantly, these changes may occur even when blood testosterone levels appear completely normal.
Because of this, professional organizations such as the American Urological Association recommend discussing fertility goals before initiating testosterone therapy, particularly in younger men who may wish to have children in the future (Mulhall et al., 2018).
What the Evidence Shows
One of the biggest misconceptions surrounding HCG is that it “preserves fertility.” The available scientific evidence is more nuanced.
Perhaps the strongest mechanistic evidence comes from the randomized dose-response study by Coviello et al. (2005). Investigators demonstrated that administering low-dose HCG during testosterone-induced gonadotropin suppression maintained intratesticular testosterone concentrations in a dose-dependent manner. Since intratesticular testosterone is essential for spermatogenesis, this finding provides a biologically plausible explanation for why HCG may help preserve aspects of testicular function during TRT.
Clinical fertility outcomes, however, are more difficult to study.
A retrospective observational study by Hsieh and colleagues followed hypogonadal men receiving testosterone therapy together with low-dose HCG. During follow-up, semen parameters remained stable and none of the participants became azoospermic (Hsieh et al., 2013). While encouraging, this study involved a relatively small number of patients, lacked randomization, and cannot establish cause and effect.
Current clinical guidelines therefore stop short of recommending HCG for every man receiving TRT. Instead, they emphasize individualized decision-making based on reproductive goals, baseline fertility status, symptoms, and patient preferences (Mulhall et al., 2018; Bhasin et al., 2018).
This distinction is important. Good medical care is based on balancing potential benefits against risks while acknowledging where evidence remains limited.
How HCG Works During TRT
Because HCG activates the same receptor as LH, it can continue stimulating Leydig cells even when endogenous LH production has been suppressed by TRT.
Maintaining this stimulation may help preserve intratesticular testosterone concentrations, which in turn may support sperm production in some patients.
However, HCG does not replace FSH, another hormone that plays an essential role in normal spermatogenesis. For men actively attempting to conceive, HCG alone may not be sufficient. Additional evaluation by a reproductive urologist or fertility specialist, semen analysis, or other medications may be necessary depending on the underlying cause of infertility.
HCG may also help maintain testicular activity, which some men perceive as preserving testicular fullness or reducing the degree of testicular atrophy associated with long-term TRT. While this outcome is commonly reported in clinical practice, high-quality randomized evidence specifically evaluating changes in testicular volume remains limited.
Like testosterone itself, HCG can influence hormone levels beyond testosterone alone. Increased estradiol production, acne, fluid retention, breast tenderness, gynecomastia, and mood changes may occur in susceptible individuals, underscoring the importance of individualized dosing and laboratory monitoring.
Rather than viewing HCG as a routine addition to every TRT protocol, current evidence supports considering it when a patient’s reproductive goals, symptoms, and clinical circumstances suggest that preserving testicular function may be beneficial.
Who May Benefit Most From Adding HCG?
Not every man receiving testosterone replacement therapy (TRT) needs HCG. Current clinical guidelines emphasize individualized treatment rather than a one-size-fits-all approach (Bhasin et al., 2018; Mulhall et al., 2018). However, several groups are more likely to benefit from discussing HCG with their healthcare provider.
Men Who Wish to Preserve Fertility
For men who plan to have children in the future—or who simply want to preserve fertility options—this is the most common reason to consider HCG alongside TRT.
Exogenous testosterone suppresses LH and FSH production through negative feedback, which can significantly reduce sperm production. In some men, prolonged TRT may lead to severe oligospermia or even azoospermia (Bhasin et al., 2018).
Because HCG mimics LH, it may help maintain intratesticular testosterone, an essential component of normal spermatogenesis. However, fertility depends on multiple factors, including FSH activity, age, baseline semen quality, genetics, and overall reproductive health. HCG should therefore be viewed as a strategy that may help preserve fertility potential, not as a guarantee of future fertility.
Men actively trying to conceive should discuss semen analysis, fertility preservation, sperm cryopreservation, or referral to a reproductive urologist before beginning TRT.
Men Concerned About Testicular Atrophy
Reduced testicular volume is a common consequence of long-term suppression of LH signaling during TRT.
Although this change is generally not harmful, some men find it physically or psychologically bothersome.
By continuing to stimulate Leydig cells, HCG may help maintain testicular activity and lessen the degree of testicular shrinkage in some patients. Individual responses vary, and no responsible clinician should promise complete prevention or reversal of testicular atrophy.
Men Considering Future Discontinuation of TRT
Some patients hope to preserve as much natural testicular function as possible in case they eventually discontinue testosterone therapy.
While this is a reasonable goal, it is important to recognize that HCG does not guarantee rapid recovery of the hypothalamic-pituitary-gonadal axis after TRT is stopped.
Recovery varies considerably depending on age, baseline endocrine function, duration of therapy, testosterone dose, underlying medical conditions, and individual biology (Bhasin et al., 2018).
Current evidence supports viewing HCG as a means of maintaining testicular stimulation during therapy rather than as insurance against future hormonal suppression.
Men Who Notice Symptomatic Differences
Some patients report improvements in libido, mood, testicular comfort, or overall well-being after HCG is added to TRT.
These experiences are clinically relevant because patient-reported outcomes are an important part of long-term hormone management. However, they should be interpreted cautiously, as large randomized clinical trials demonstrating consistent symptomatic benefits remain limited.
Changes in testosterone, estradiol, and intratesticular hormone production may all contribute to differences in how patients feel. Any improvements—or new side effects—should be evaluated alongside laboratory findings and clinical follow-up.
Why Some Clinics Do Not Routinely Prescribe HCG
The absence of HCG from a TRT protocol does not necessarily indicate poor medical care.
Many patients have completed family planning, have no concerns about testicular volume, or simply do not have a clinical indication for additional medication. For these individuals, testosterone alone may be an appropriate treatment.
HCG also increases treatment complexity. It requires another prescription, proper storage after reconstitution, additional injections, and periodic laboratory monitoring. Like all medications, it may also cause adverse effects, including acne, fluid retention, breast tenderness, gynecomastia, mood changes, headaches, and elevated estradiol levels.
What matters most is not whether every patient receives HCG, but whether fertility goals and reproductive health are discussed before treatment begins. A comprehensive evaluation should explain both the potential benefits and the limitations of HCG based on the best available evidence.
Common HCG Dosing Approaches
There is no universally appropriate HCG dose for men receiving TRT.
Published clinical studies have evaluated doses ranging from 250 IU to 500 IU administered two to three times per week, with adjustments based on treatment goals and laboratory response (Coviello et al., 2005). In clinical practice, physicians may individualize dosing according to fertility considerations, symptom control, testosterone concentrations, estradiol levels, and tolerability.
These dosing ranges are provided for educational purposes only and should not be interpreted as personal medical advice. The use of HCG alongside TRT is commonly considered an off-label application, and treatment decisions should always be made by a licensed healthcare professional after appropriate evaluation.
Monitoring may include:
- Total and free testosterone
- Estradiol
- Hematocrit and hemoglobin
- Liver and metabolic markers when indicated
- Semen analysis when fertility is a treatment goal
- Ongoing assessment of symptoms and adverse effects
Regular follow-up allows clinicians to adjust therapy while minimizing unnecessary risks.
Risks and Potential Side Effects
Like any prescription medication, HCG has potential side effects.
Some men experience few or no problems, while others may develop adverse effects related to increased testosterone or estradiol production.
Potential side effects include:
- Acne or oily skin
- Fluid retention
- Breast tenderness
- Gynecomastia
- Mood changes
- Injection-site discomfort
- Headache
- Elevated estradiol levels
Serious complications are uncommon when HCG is prescribed appropriately and monitored regularly, but no medication is entirely risk-free.
Patients should promptly report new symptoms to their healthcare provider rather than adjusting medication on their own.
Related Reading:
HGH Plus Testosterone Therapy May Provide Relief From Back Pain, Study Finds
Testosterone Therapy Can Improve Urinary and Sexual Function in Men with Low T
A List of Herbs That Are Proven to Safely Increase Testosterone Levels
Critics say the HGH and Testosterone Industry Is Using Disease Mongering To Boost Sales
How Testosterone Injections Lengthened a 34 Year Old Man’s Penis
Choosing a Clinic That Discusses HCG
Before beginning TRT, ask whether fertility goals, reproductive plans, and long-term hormone management are discussed during the initial consultation rather than after treatment has already started.
A comprehensive evaluation should include:
- Review of symptoms and medical history
- Appropriate laboratory testing
- Discussion of fertility goals
- Explanation of expected benefits and limitations
- Ongoing monitoring and follow-up
Patients should receive individualized recommendations based on their symptoms, laboratory findings, reproductive goals, and overall health. If you’d like to see an example of HCG as part of a supervised TRT protocol, this resource explains how one provider evaluates candidates before prescribing treatment. Regardless of where care is received, eligibility should always be determined by a licensed clinician following an individualized medical assessment, and prescriptions are never guaranteed.
Final Thoughts
Human chorionic gonadotropin plays a different role than testosterone replacement therapy. Rather than replacing testosterone, HCG mimics the action of luteinizing hormone, helping maintain the hormonal signaling that supports normal testicular function.
Current evidence suggests that HCG may help preserve intratesticular testosterone and support spermatogenesis in appropriately selected men receiving TRT, particularly those with fertility concerns (Coviello et al., 2005). At the same time, the available evidence has important limitations. HCG does not guarantee fertility preservation, prevent every consequence of gonadotropin suppression, or ensure recovery of natural testosterone production after TRT is discontinued.
For that reason, HCG should not be viewed as a routine addition to every testosterone protocol. Instead, it should be considered within the context of an individualized treatment plan developed after careful evaluation of symptoms, laboratory findings, reproductive goals, medical history, and patient preferences.
The best TRT programs are those that encourage informed decision-making, explain the strength of the available evidence, acknowledge where uncertainties remain, and tailor treatment to the individual rather than relying on standardized protocols.
References
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Wu, F. C. W. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
Coviello, A. D., Matsumoto, A. M., Bremner, W. J., Herbst, K. L., Amory, J. K., Anawalt, B. D., Yan, X., Brown, T. R., Wright, W. W., & Zirkin, B. R. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. The Journal of Clinical Endocrinology & Metabolism, 90(5), 2595–2602. https://doi.org/10.1210/jc.2004-0802
Hsieh, T. C., Pastuszak, A. W., Hwang, K., & Lipshultz, L. I. (2013). Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. The Journal of Urology, 189(2), 647–650. https://doi.org/10.1016/j.juro.2012.09.043
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., Platz, E. A., Ramanathan, L. V., & Lewis, R. W. (2018). Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology, 200(2), 423–432. https://doi.org/10.1016/j.juro.2018.03.115
